A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults

• Status: Completed
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the effectiveness of RXI-109 in reducing the recurrence of keloid formation following elective keloid excision.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: RXi Pharmaceuticals, Corp.

Criteria

Inclusion Criteria:

• Adults, 21-55 years of age.

• Two keloids of approximately similar size and anatomical location on the earlobe, neck, or torso.

• Keloids to be excised must have been present for > 1 year.

Exclusion Criteria:

• Use of tobacco or nicotine-containing products

• Pregnant or lactating

• Post-menopausal or full hysterectomy